Theravance Biopharma Inc. (NASDAQ:TBPH) shares fell 0.4% on Friday . The stock traded as low as $22.90 and last traded at $22.90, with a volume of 85,365 shares traded. The stock had previously closed at $23.00.

Several research firms have recently weighed in on TBPH. Leerink Swann reaffirmed a “buy” rating on shares of Theravance Biopharma in a report on Saturday, June 4th. Bank of America Corp. cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating in a report on Thursday, May 5th. Guggenheim began coverage on shares of Theravance Biopharma in a report on Monday, June 20th. They issued a “buy” rating and a $30.00 price target on the stock. Zacks Investment Research cut shares of Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Tuesday, April 19th. Finally, TheStreet raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Monday, March 21st. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $24.33.

The company’s market capitalization is $1.11 billion. The stock has a 50-day moving average of $22.69 and a 200 day moving average of $19.06.

Theravance Biopharma (NASDAQ:TBPH) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.14. The company had revenue of $18.40 million for the quarter, compared to the consensus estimate of $18.69 million. Equities research analysts predict that Theravance Biopharma Inc. will post ($4.24) EPS for the current fiscal year.

A hedge fund recently raised its stake in Theravance Biopharma stock. OppenheimerFunds Inc. raised its stake in Theravance Biopharma Inc. (NASDAQ:TBPH) by 1.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,103,485 shares of the biopharmaceutical company’s stock after buying an additional 12,120 shares during the period. OppenheimerFunds Inc. owned 2.92% of Theravance Biopharma worth $18,086,000 at the end of the most recent quarter.

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.